BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected

Group 1 - BioSig Technologies, Inc. has provided an update regarding the status of its merger with Streamex Exchange Corporation, indicating that the acquisition proposal will be adjourned pending final NASDAQ approval [1][3] - The merger transaction was officially closed on May 28, 2025, with 19.99% of BioSig shares already issuable to Streamex shareholders, while the remaining shares await NASDAQ approval [2][4] - The Board of Directors has decided to postpone Proposal No. 1 (the Acquisition Proposal) to a later date due to the pending NASDAQ approval, but all other proposals will proceed as planned at the Special Meeting on September 5, 2025 [3][4] Group 2 - Streamex is a company focused on RWA tokenization, aiming to create institutional-grade infrastructure for the gold and commodities market, supported by a gold-denominated treasury and tokenization technology [5] - BioSig Technologies specializes in medical device technology, particularly with its PURE EP™ Platform, which provides insights for electrophysiologists in the treatment of cardiovascular arrhythmias [6]